SkinBioTherapeutics - CEO Designate Appointment
("SkinBioTherapeutics" or the "Company")
CEO Designate Appointment
The intention is for
Stuart brings over two decades of commercial experience, primarily in the medical devices industry, having held senior-level positions in a range of large public and smaller private companies.
Since 2014, Stuart has served as CEO of
Prior to Onbone, Stuart was President/CEO of
Prior to his career in industry, Stuart served in the armed forces. He has an MBA and a BSc in Business & Management.
"On behalf of the
"We intend for Stuart to take on this exciting opportunity from Cath, who has played a pivotal role as CEO, from discovering the technology, to founding the Company and leading it through the IPO and its early life as a listed company. Her ongoing involvement ensures the Company will continue to benefit from her substantial knowledge and expertise."
"SkinBioTherapeutics has developed from a solid scientific foundation founded by Cath. The Company's technology, SkinBiotixÒ, is well placed in an increasingly active market segment and it will be a tremendous opportunity to work with Cath and the team to grow the business further. Upon appointment, my immediate focus for the Company will be to continue to support the clinical development of the technology whilst building on the ongoing commercial discussions."
The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 and has been arranged for release by
For more information please contact:
Tel: +44 (0) 161 468 2760
Tel: +44 (0) 20 7213 0880
Turner Pope Investments (Joint Broker)
SP Angel Corporate Finance (Joint Broker)
Tel: +44 (0) 20 3621 4120
Tel: +44 (0) 20 3470 0470
| || |
Tel: +44 (0) 20 7457 2020
SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by Dr.
SkinBioTherapeutics' platform applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to the skin. The Company has shown that the SkinBiotix® platform can improve the barrier effect of skin models, protect skin models from infection and repair skin models. Proof of principle studies have shown that the SkinBiotix® platform has beneficial attributes applicable to each of these areas.
SkinBioTherapeutics received seed funding from the Tech Transfer office of the
The Company joined AIM in
The Company is based in
This information is provided by RNS, the news service of the
Quick facts: SkinBioTherapeutics PLC
Market Cap: £21.45 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE